We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Press Releases

Press Releases

Mar 19, 2019

NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS- 1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol®

READ PRESS RELEASE

Feb 21, 2019

NLS-1 Pharma and Eurofarma Enter to an Exclusive Licensing Agreement to Develop and Commercialize Nolazol® for the Treatment of ADHD in Latin America

READ PRESS RELEASE

Sept 1, 2018

CEO of NLS-1 Pharma AG is honored with Several Illustrious Awards This Summer

READ PRESS RELEASE

Mar 24, 2018

NLS-1 Pharma Is Awarded “Best Quality of Life Improvement Pharmaceuticals Company – Central Europe” by Global Health & Pharma Magazine

READ PRESS RELEASE

Feb 5, 2018

NLS-1 Presents Positive Phase 2 Study Results for Mazindol at APSARD

READ PRESS RELEASE VIEW POSTER

Oct 31, 2017

NLS-1 Pharma Announces Poster Presentation On Efficacy and Safety Data of a Controlled Release (CR) Formulation of Mazindol in Adults with ADHD at AACAP’s & APSARD’s Annual Meeting in the US

READ PRESS RELEASE

Oct 9, 2017

NLS-1 wins prestigious Innovation Award in Paris. Over 300 candidates participated in the race.

READ MORE

May 31, 2017

NLS-1 Pharma unveils positive phase 2 data for NLS-1 (Mazindol CR) in adults with ADHD, demonstrating significant improvement in symptoms

READ PRESS RELEASE

May 26, 2017

NLS-1 Pharma announces new information in support of the mechanism of action of its lead compound NLS-1 Mazindol CR

READ PRESS RELEASE

May 16, 2017

NLS-1 Pharma announces phase 2 study of NLS-1 (MAZINDOL) in adult ADHD patients has met all primary and secondary endpoints

READ PRESS RELEASE

April 20, 2017

NLS-1 Pharma Announces Presentations at 6th World Congress on ADHD

READ PRESS RELEASE

April 18, 2017

NLS-1 Pharma Announces Completion of Phase 2 Study for NLS-1, Its Lead ADHD Compound; New Investors, New Patents

READ PRESS RELEASE

December 3, 2016

NLS-1 Pharma Named Winner Of A Prestigous 2016 Healthcare & Life Sciences Award

READ PRESS RELEASE

August 29, 2016

NLS-1 Pharma announces start of its phase 2 trial for Mazindol in adult ADHD patients

READ PRESS RELEASE

July 11, 2016

Mazindol granted orphan drug designation in the US & Europe for treatment of Narcolepsy

READ PRESS RELEASE

June 16, 2016

FDA accepts IND for Phase II Study of Mazindol in Adults with ADHD

READ PRESS RELEASE

May 12, 2016

NLS-1 Pharma Announces IND submission for Controlled-Release Mazindol to Treat Adults with ADHD.

READ PRESS RELEASE